{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-000769","form_type":"8-K","ticker":"ACRS","cik":"0001557746","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2024-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.600292+00:00","generated_at":"2026-06-06T09:08:48.793615+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aclaris terminates CMO, enters separation with former CEO; promotes CSO to full-time","bullets":["Terminated Gail Cawkwell as CMO effective Jan 31, 2024, without cause; receives 12-month salary continuation and COBRA coverage.","Entered separation agreement with former CEO Douglas Manion on Feb 4, 2024; receives 12-month salary continuation plus unpaid 2023 bonus.","Amended CSO Joseph Monahan's employment; base salary raised to $430,000, moves from part-time to full-time effective Feb 1, 2024.","Monahan’s new agreement has a 2-year initial term with automatic one-year renewals unless 90-day notice is given."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-000769","json":"https://secwatch.observer/filing/0001558370-24-000769.json","markdown":"https://secwatch.observer/filing/0001558370-24-000769.md","text":"https://secwatch.observer/filing/0001558370-24-000769.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024000769/0001558370-24-000769-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024000769/acrs-20240131x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T09:08:48.793615+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3c01a83b3a","claim":"Douglas Manion departed as Chief Executive Officer and President at Aclaris Therapeutics, Inc..","evidence_excerpt":"On February 4, 2024, in connection with Douglas Manion’s departure from the Company as the Company’s Chief Executive Officer and President, the Company and Dr. Manion entered into a Separation Agreement","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024000769/0001558370-24-000769-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Chief Executive Officer and President"}],"fact_type":"executive_change"},{"claim_id":"92b8bea230","claim":"Gail Cawkwell was terminated as Chief Medical Officer at Aclaris Therapeutics, Inc..","evidence_excerpt":"On January 31, 2024, Aclaris Therapeutics, Inc. (the “ Company ”) terminated the employment of Gail Cawkwell, M.D., PhD., the Company's Chief Medical Officer, without cause, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024000769/0001558370-24-000769-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}